FDA Approves Invega for Schizophrenia

On Wednesday, the Food and Drug AdministrationThis comes to good news to those suffering from
approved extended release Invega for the treatmentschizophrenia. The National Institute of Mental Health
of schizophrenia.states, "Schizophrenia is a chronic, severe, and
The approval was based on the results of 3, 6 weekdisabling brain disorder that affects about 1 percent
studies which were conducted in North America,of people all over the world. People with
Europe, Asia, and involved 1,665 participants. Theseschizophrenia sometimes hear voices others don't
studies concluded that Invega was more effectivehear, believe that others are broadcasting their
than a placebo for relieving symptoms associatedthoughts to the world, or become convinced that
with schizophrenia.others are plotting to harm them. These experiences
The patients in the group were given dosescan make them fearful and withdrawn and cause
medication from 3 milligrams to 15 milligrams a day.difficulties when they try to have relationships with
Although minor, some of the side affectsothers."
experienced by patients included restlessness,According to Healthday, the FDA concluded that
movement disorders, rapid heart beat, and sleepiness.since the medication has not been tested for a
Also, Invega belongs to the class of drugs calledperiod over 6 weeks, patients taking the medication
atypical antipsychotic which have been linked to anlong term should schedule regular visits to be
increased rate of death among elderly patients withmonitored by a licensed physician.
dementia related psychosis. Thankfully this relates toVisit this Consumer Advocacy website for more
a very small percentage of users.information on ordering from online no prescription.